Background and Need for Legislation
Vector-borne diseases (VBDs) pose an escalating threat to
the public's health within the United States. A vector is a
mosquito, tick, or flea that can spread pathogens, and the
annual number of reported cases of vector-borne disease has
doubled over the past two decades.\1\ In 2019, 50,865 of the
56,045 VBDs cases reported to CDC were tickborne diseases.\2\
Lyme Disease currently accounts for more than 70 percent of
these reported tick disease cases.\3\ It is estimated that
about 476,000 people are diagnosed and treated for Lyme disease
annually in the U.S.\4\
---------------------------------------------------------------------------
\1\Ctrs. for Disease Control and Prevention (CDC), National Public
Health Strategy to Prevent and Control Vector-Borne Diseases in People
(Dec. 22, 2025), https:www.cdc.gov/vector-borne-diseases/php/data-
research/national-strategy/index.html.
\2\Id.
\3\CDC, A National Public Health Framework for the Prevention and
Control of Vector-Borne Diseases in Humans (Sept. 2020), https://
www.cdc.gov/vector-borne-diseases/media/pdfs/
Brochure_National_Framework_VBDs-P.pdf.
\4\Supra note 1.
---------------------------------------------------------------------------
The mosquitos, ticks, and fleas that carry dangerous
diseases are expanding their habitat within the United
States.\5\ To date, there are no vaccines and limited treatment
options for tickborne illnesses.\6\ The VBD National Strategy
is led by the Department of Health and Human Services and has
six participating federal departments, allowing for a
coordinated approach to VBD prevention and control.
---------------------------------------------------------------------------
\5\Id.
\6\Johns Hopkins Bloomberg School of Public Health, Ticks Pose an
Increasing Health Risk (Apr. 30, 2025), https://publichealth.jhu.edu/
2025/tickborne-diseases-in-the-us.
---------------------------------------------------------------------------
In addition to the development of the VBD National
Strategy, the 2019 Kay Hagan Tick Act established Regional
Centers of Excellence in Vector-Borne Disease, located at
universities in California, Florida, Texas, and Wisconsin. The
law and directs CDC to enter into cooperative agreements across
the United States with health departments in areas at high risk
of vector-borne diseases.\7\ These cooperative agreements
support better data collection and analysis, earlier detection
and diagnosis, as well as improve treatments and awareness
around VBDs.
---------------------------------------------------------------------------
\7\Office of the Assistant Secretary for Health (OASH), Vector
Borne Disease National Strategy, The Kay Hagan Tick Act (Aug. 27,
2023), https://health.gov/about-oash/io-programs-
initiatives/innovationx/vector-borne-disease-national-strategy/kay-
hagan-tick-act.
---------------------------------------------------------------------------
Committee Action
On April 15, 2026, the Subcommittee on Health held a
hearing on H.R. 4348. The title of the hearing was ``Healthier
America: Legislative Proposals to Improve Public Health.'' The
Subcommittee received testimony from:
Jamie Ulmer, MA, President and CEO,
Healthcare Network
Rachel F. Brem, MD, FACR, FSBI, Co-Founder,
Chief Medical Officer, Brem Foundation to Defeat Breast
Cancer and Professor and Vice-Chair Emeritus, The
George Washington University
Holly Ahern, MS, MT(ASCP), Associate
Professor of Microbiology, State University of New York
Adirondack
Amy L. Ronneberg, MBA, Chief Executive
Officer, National Marrow Donor Program
Brian Wallach & Sandra Abrevaya, Co-
Founders, I AM ALS
Rene Quashie, JD, Vice President, Digital
Health, Consumer Technology Association
On May 13, 2026, the Subcommittee on Health met in open
markup session and forwarded H.R. 4348, without amendment, to
the full Committee by a voice vote.
On May 21, 2026, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 4348, without
amendment, favorably reported to the House by a record vote of
48 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
reauthorize the National Strategy and Regional Centers of
Excellence in Vector-Borne Disease and the Centers for Disease
Control and Prevention's (CDC) cooperative agreements with
health departments in areas at high risk of vector-borne
diseases through Fiscal Year 2030.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 4348 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearings were used to develop or consider H.R. 4348:
On April 15, 2026, the Subcommittee on
Health held a legislative hearing on H.R. 4348. The
title of the hearing was ``Healthier America:
Legislative Proposals to Improve Public Health.'' The
Subcommittee received testimony from:
Jamie Ulmer, MA, President and
CEO, Healthcare Network;
Rachel F. Brem, MD, FACR, FSBI,
Co-Founder, Chief Medical Officer, Brem
Foundation to Defeat Breast Cancer and
Professor and Vice-Chair Emeritus, The George
Washington University;
Holly Ahern, MS, MT(ASCP),
Associate Professor of Microbiology, State
University of New York Adirondack;
Amy L. Ronneberg, MBA, Chief
Executive Officer, National Marrow Donor
Program;
Brian Wallach & Sandra Abrevaya,
Co-Founders, I AM ALS; and,
Rene Quashie, JD, Vice
President, Digital Health, Consumer Technology
Association.
On April 21, 2026, the Subcommittee on
Health held a hearing on H.R. 4348. The title of the
hearing was ``The Fiscal Year 2027 Department of Health
and Human Services Budget.'' The Subcommittee received
testimony from:
The Honorable Robert F. Kennedy
Jr., Secretary, U.S. Department of Health and
Human Services.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 4348 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Reauthorization of programs
Section 1 reauthorizes the National Strategy and Regional
Centers of Excellence in Vector-Borne Disease and the CDC's
cooperative agreements with health departments in areas at high
risk of vector-borne diseases through Fiscal Year 2030.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE
* * * * * * *
Part B--Federal-State Cooperation
* * * * * * *
SEC. 317U. NATIONAL STRATEGY AND REGIONAL CENTERS OF EXCELLENCE IN
VECTOR-BORNE DISEASES.
(a) In General.--The Secretary shall--
(1)(A) ensure the development and implementation of a
national strategy to address vector-borne diseases,
including tick-borne diseases, that--
(i) identifies and assesses gaps and any
unnecessary duplication in federally-funded
programs; and
(ii) identifies strategic goals to address
such diseases and appropriate benchmarks to
measure progress toward achieving such goals;
and
(B) update such strategy, as appropriate; and
(2) coordinate programs and activities, including
related to data collection, research, and the
development of diagnostics, treatments, vaccines, and
other related activities, to address vector-borne
diseases, including tick-borne diseases, across the
Department of Health and Human Services and with other
Federal agencies or departments, as appropriate.
(b) Consultation.--In carrying out subsection (a)(1), the
Secretary shall consult with [the Tick-Borne Disease Working
Group established under section 2062 of the 21st Century Cures
Act (42 U.S.C. 284s) and other individuals, as appropriate]
appropriate individuals, such as--
(1) epidemiologists with experience in vector-borne
diseases;
(2) representatives of patient advocacy and research
organizations that focus on vector-borne diseases,
including such organizations that have demonstrated
experience in related research, public health, data
collection, or patient access to care;
(3) health information technology experts or other
information management specialists;
(4) clinicians, entomologists, vector management
professionals, public health professionals, and others
with expertise in vector-borne diseases; and
(5) researchers, including researchers with
experience conducting translational research.
(c) Centers of Excellence.--The Secretary, in coordination
with the Director of the Centers for Disease Control and
Prevention, shall award grants, contracts, or cooperative
agreements to institutions of higher education for the
establishment or continued support of regional centers of
excellence in vector-borne diseases to address vector-borne
diseases, including tick-borne diseases, by--
(1) facilitating collaboration between academia and
public health organizations for public health
surveillance, prevention, and response activities
related to vector-borne diseases, including tick-borne
diseases;
(2) providing training for public health
entomologists and other health care professionals, as
appropriate, to address vector-borne diseases,
including tick-borne diseases;
(3) conducting research to develop and validate
prevention and control tools and methods, including
evidence-based and innovative, evidence-informed tools
and methods to anticipate and respond to disease
outbreaks; or
(4) preparing for and responding to outbreaks of
vector-borne diseases, including tick-borne diseases,
including by increasing capacity to identify, report,
prevent, and respond to such diseases.
(d) Eligibility.--To be eligible to receive a grant,
contract, or cooperative agreement under subsection (c), an
entity shall submit to the Secretary an application at such
time, in such manner, and containing such information as the
Secretary may require, including a description of how the
entity will conduct the activities described in such
subsection.
(e) Reports.--
(1) Program summary.--An entity receiving an award
under subsection (c) shall, not later than one year
after receiving such award, and annually thereafter,
submit to the Secretary a summary of programs and
activities funded under the award.
(2) Progress report.--Not later than 4 years after
the date of enactment of this section, the Secretary
shall submit to the Committee on Health, Education,
Labor, and Pensions of the Senate and the Committee on
Energy and Commerce of the House of Representatives, a
report on the progress made in addressing vector-borne
diseases, including tick-borne diseases, through
activities carried out under this section.
(f) Authorization of Appropriations.--For the purpose of
carrying out this section, there are authorized to be
appropriated $10,000,000 for each of fiscal years [2021 through
2025] 2026 through 2030.
* * * * * * *
TITLE XXVIII--NATIONAL ALL-HAZARDS PREPAREDNESS FOR PUBLIC HEALTH
EMERGENCIES
* * * * * * *
Subtitle C--Strengthening Public Health Surveillance Systems
* * * * * * *
SEC. 2822. ENHANCED SUPPORT TO ASSIST HEALTH DEPARTMENTS IN ADDRESSING
VECTOR-BORNE DISEASES.
(a) In General.--The Secretary, acting through the Director
of the Centers for Disease Control and Prevention, may enter
into cooperative agreements with health departments of States,
political subdivisions of States, and Indian Tribes and Tribal
organizations in areas at high risk of vector-borne diseases in
order to increase capacity to identify, report, prevent, and
respond to such diseases and related outbreaks.
(b) Eligibility.--To be eligible to enter into a cooperative
agreement under this section, an entity described in subsection
(a) shall prepare and submit to the Secretary an application at
such time, in such manner, and containing such information as
the Secretary may require, including a plan that describes--
(1) how the applicant proposes to develop or expand
programs to address vector-borne disease risks,
including through--
(A) related training and workforce
development;
(B) programmatic efforts to improve capacity
to identify, report, prevent, and respond to
such disease and related outbreaks; and
(C) other relevant activities identified by
the Director of the Centers for Disease Control
and Prevention, as appropriate;
(2) the manner in which the applicant will coordinate
with other Federal, Tribal, and State agencies and
programs, as applicable, related to vector-borne
diseases, as well as other relevant public and private
organizations or agencies; and
(3) the manner in which the applicant will evaluate
the effectiveness of any program carried out under the
cooperative agreement.
(c) Authorization of Appropriations.--For the purposes of
carrying out this section, there are authorized to be
appropriated $20,000,000 for each of fiscal years [2021 through
2025] 2026 through 2030.
* * * * * * *
[all]